Related Experiment Video

Updated: Jul 7, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.6K

The influence of a modified p53 C-terminal peptide by using a tumor-targeting sequence on cellular apoptosis and

Xiaoye Guo1, Yiming Zhang1, Qian Li1

  • 1School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, 210009, Nanjing, P.R. China.

Apoptosis : an International Journal on Programmed Cell Death
|December 25, 2023
PubMed

Insights

Restoring p53 tumor suppressor function is key. A new peptide, P462, enhances drug delivery to tumors by incorporating a tumor-targeting sequence, improving cancer treatment efficacy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The TP53 tumor suppressor gene is frequently mutated in cancers.
  • Restoring p53 function is a promising therapeutic strategy.
  • Poor drug accumulation in tumors limits treatment effectiveness.

Purpose of the Study:

  • To enhance the anti-tumor activity of the p53 C-terminus peptide (P460).
  • To improve tumor drug delivery and accumulation.
  • To evaluate a novel peptide (P462) incorporating a tumor-targeting sequence.

Main Methods:

  • Peptide synthesis: P460 modified with Arg-Gly-Asp-Arg (RGDR) to create P462.
  • In vitro assays: Cancer cell proliferation and apoptosis.
  • In vivo studies: Tumor imaging, drug accumulation, and therapeutic efficacy.
  • Cell adhesion analysis.

Main Results:

  • P462 demonstrated enhanced inhibition of cancer cell proliferation and increased apoptosis compared to P460.
  • P462 exhibited more specific and extensive binding to tumor cells.
  • P462 showed greater tumor accumulation and improved in vivo efficacy.
  • RGDR sequence significantly enhanced cell attachment and tumor homing.

Conclusions:

  • The novel peptide P462, with its integrated RGDR tumor-targeting sequence, significantly improves anti-tumor activity.
  • P462 offers enhanced tumor homing and accumulation, addressing a key challenge in cancer therapy.
  • P462 represents a potential novel drug candidate for effective tumor treatment.
Keywords:
C-end rule peptideCell adhesionTumor-targetingp53

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.3K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K